ARID1A and neoplasm: As a tumor suppressor, ARID1A loss is correlated with tumor progression, with its frequency increasing with tumor-node-metastasis (TNM) stage: 7.4% in stage I, 24.1% in stage II, 22.2% in stage III, and 46.3% in stage IV.